NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Bora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Facility: FAQ
Bora Pharmaceuticals acquired MacroGenics' biologics drug substance manufacturing operations in Rockville, MD, for $122.5M, expanding its US biologics platform to 20,000 liters of single-use bioreactor capacity. This establishes a fully integrated, US-based CDMO platform supporting development through commercial supply, with clean FDA inspection results.
Bora acquired the GMP manufacturing operations of MacroGenics, including its biologics drug substance facility in Rockville, Maryland, and an associated warehousing center in Frederick, Maryland, for $122.5 million.
It establishes a 20,000-liter US biologics drug substance manufacturing platform with two active US sites, reducing offshore dependency and offering end-to-end biologics CDMO services from development to commercial supply.
Sponsors gain access to a US-based, inspection-proven infrastructure with clean FDA and PMDA inspections, supporting more than 4 commercial programs and over 120 completed GMP batches for global markets.
The total consideration for the acquisition was US $122.5 million.
The acquisition was announced as completed on July 2, 2026.
Bora Biologics operates in Rockville, Maryland; San Diego, California; and a development facility in Zhubei, Taiwan.
The US network has completed five FDA inspections (including two at Rockville) and one PMDA review in 2025, all with clean results.
Yes, Bora intends to integrate its US drug substance capabilities with existing sterile drug product capabilities over the next 12 to 18 months.
Bobby Sheng is the Chairman and CEO of Bora Group.
Visit Bora's website at https://www.bora-corp.com or https://www.boracdmo.com.